What are the key milestones or upcoming data readouts for the TRACTr, TRACIr, and ARM platforms in the next 12 months?

Based on the excerpt you provided from Janux Therapeutics’ August 7 2025 Business Wire release, the company’s press release highlights its overall financial performance and gives a brief, high‑level description of its three technology platforms—TRACTr (Tumor‑Activated T‑Cell Engager), TRACIr (Tumor‑Activated Immunomodulator) and ARM (Adaptive Immune Response Modulator). However, the excerpt does not contain any specific details about upcoming milestones, data readouts, or other planned activities for any of those platforms in the coming 12‑month period.

What the release does say:

• Janux is a clinical‑stage biopharmaceutical company developing a broad pipeline of novel immunotherapies.
• The company is applying its proprietary technologies to the three platforms (TRACTr, TRACIr, ARM) mentioned.
• The press release focuses on the company’s second‑quarter 2025 financial results and a general business update.

What the release does not say:

• No specific clinical trial phases, patient‑enrollment timelines, or data‑readout dates for any TRACTr, TRACIr, or ARM candidates.
• No mention of upcoming presentations at scientific conferences (e.g., ASCO, AACR) or expected filing dates (e.g., IND submissions, FDA meetings) for any of the platform programs.
• No details about upcoming preclinical data, Phase 1/2 trial start dates, or expected readout dates for efficacy or safety data.

Conclusion

The news snippet you supplied does not provide the specific milestones or upcoming data readouts for the TRACTr, TRACIr, or ARM platforms in the next 12 months. To obtain that information, you would need to consult the full press release (or a more detailed investor‑relations presentation) where the company typically lists:

• Planned start‑dates for early‑phase clinical trials.
• Expected interim data readouts (e.g., safety or pharmacodynamic data) at upcoming scientific conferences.
• Regulatory milestones (e.g., IND filings, IND‑NDA meetings, or FDA/EMA interactions).

If you can locate the complete press release or a supplemental investor‑presentation, those documents usually contain a timeline or “up‑coming milestones” slide that would give the exact dates and milestones you’re looking for. If you can share that additional text, I can extract and summarize the specific milestones for each platform.